Characterization of TCF-1 and its relationship between CD8+ TIL densities and immune checkpoints and their joint influences on prognoses of lung adenocarcinoma patients

Thorac Cancer. 2023 Sep;14(27):2745-2753. doi: 10.1111/1759-7714.15058. Epub 2023 Aug 3.

Abstract

Background: T cell factor-1 (TCF-1) + stem-like tumor-infiltrating lymphocytes (stem-like TILs) are important memory cells in the tumor microenvironment. However, their relationship with clinicopathological features, CD8+ TIL densities, immune checkpoint inhibitors (ICs), and prognostic values remain unknown for lung adenocarcinomas (LUADs). In this study, we aimed to characterize TCF-1+ TILs and their prognostic significance in patients with surgically resected LUADs.

Methods: Expression of TCF-1, CD8, and ICs including programmed death-1 (PD-1), lymphocyte activating-3 (LAG-3), and T cell immunoglobulin and mucin-domain containing-3 (TIM-3) in TILs were estimated using immunohistochemistry of resected LUADs. The association between TCF-1 expressions and clinicopathological characteristics of patient prognoses were analyzed.

Results: Positive TCF-1 expression significantly correlated with advanced pathological stage, tumor grade, CD8+ TILs density, TIM-3 expression, LAG-3 expression, and PD-1 expression. TCF-1 positivity was significantly associated with a better recurrence-free survival (RFS), and overall survival (OS). Subgroup analysis revealed that the TCF-1+/CD8+ group had the best RFS and OS, while the TCF-1-/CD8- group had the worst RFS and OS. Similarly, patients with TCF-1 + PD-1- had the best prognoses and patients with TCF-1-PD-1+ had the worst prognoses.

Conclusion: TCF-1 had relatively high positive expression and special clinicopathological features in patients with LUAD. TCF-1+ TILs were related to CD8 density, TIM-3 expression, LAG-3 expression, and PD-1 expression, and were associated with better prognoses in LUAD patients. A combination of TCF-1 and CD8 densities or PD-1 expression further stratified patients into different groups with distinct prognoses.

Keywords: T cell factor-1 (TCF-1); cluster of differentiation 8 (CD8); immune checkpoint inhibitors (ICs); lung adenocarcinoma (LUAD); prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung*
  • Adenocarcinoma*
  • B7-H1 Antigen / metabolism
  • CD8-Positive T-Lymphocytes / metabolism
  • Hepatitis A Virus Cellular Receptor 2
  • Humans
  • Lung Neoplasms* / pathology
  • Prognosis
  • Programmed Cell Death 1 Receptor / metabolism
  • Tumor Microenvironment

Substances

  • B7-H1 Antigen
  • Hepatitis A Virus Cellular Receptor 2
  • Programmed Cell Death 1 Receptor
  • HNF1A protein, human